Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

The Latest: CDC head acknowledges confusion over boosters

09/26/2021 | 02:13pm EDT

WASHINGTON — The head of the Centers for Disease Control and Prevention says she recognizes there’s some confusion now in the United States about who should get a COVID-19 vaccine booster.

For starters, the just-approved booster is intended for people originally vaccinated with shots made by Pfizer and its partner BioNTech.

Last week, CDC Director Dr. Rochelle Walensky sided with most of the recommendations from CDC advisers on giving boosters six months after the last Pfizer dose for certain groups of people.

That includes people 65 and older, nursing home residents and people ages 50 to 64 with chronic health problems such as diabetes. People 18 and older with health problems can decide for themselves if they want a booster.

But Walensky also overrode advisers’ objections and said people at increased risk of infection because of their jobs or their living conditions could qualify for a booster now. That includes health care workers, teachers and people in jails or homeless shelters.

“I recognize that confusion right now,” Walensky told CBS’ “Face the Nation.”

“We are evaluating this science in real time," she said.l "We are meeting every several weeks now to evaluate the science. The science may very well show that the rest of the population needs to be boosted and we will provide those guidances as soon as we have the science to inform them.”

People who got the Moderna or Johnson & Johnson vaccines are waiting to hear when they might be eligible for a booster.

MORE ON THE PANDEMIC:

U.S. has enough COVID-19 vaccines for boosters, kids' shots

UK counts on vaccines, ‘commen sense,’ to keep virus at bay

— EXPLAINER: Who’s eligible for Pfizer booster shots in US?

See all of AP's pandemic coverage at https://apnews.com/hub/coronavirus-pandemic

HERE’S WHAT ELSE IS HAPPENING:

WASHINGTON — Pfizer’s CEO says “it’s a question of days, not weeks” before the company and German partner BioNTech submit data to U.S. regulators for federal authorization of a COVID-19 vaccine for children age 5 to 11.

That would be an important step toward starting vaccinations for those youngsters, especially with kids now back in school and the delta variant resulting in a big jump in pediatric infections.

Pfizer said last week that its vaccine works for that age group and that it tested a much lower dose of the vaccine that’s already available for anyone 12 and older. The company said that after children age 5 to 11 got their second dose during testing, they developed coronavirus-fighting antibody levels just as strong as teenagers and young adults getting the regular-strength shots

Pfizer CEO Albert Bourla said Sunday that if the Food and Drug Administration approves the company’s application, “we will be ready with our manufacturing to provide this new formulation of the vaccine.”

And when it comes to the coronavirus pandemic, he told ABC’s “This Week” that within a year, “I think we will be able to come back to normal life. I don’t think that this means that variants will not be continuing coming. And I don’t think that this means that we should be able to live our lives … without having vaccinations, basically.”

Bourla also said “we will have vaccines that … will last at least a year’’ and that “the most likely scenario, it is annual revaccinations.”

HELSINKI — Police in Norway have reported dozens of disturbances and violent clashes, including mass brawls in the Nordic country’s big cities, after streets, bars, restaurants and nightclubs were filled with people celebrating the end of COVID-19 restrictions.

The Norwegian government abruptly announced Friday that most of the remaining coronavirus restrictions would be scrapped from Saturday and that life in the nation of 5.3 million would return to normal.

The unexpected announcement by Prime Minister Erna Solberg late Friday afternoon to drop coronavirus restrictions the next day took many Norwegians by surprise and led to chaotic scenes in the capital, Oslo, and elsewhere in the country on Saturday.

Rowdy celebrations across Norway by hundreds of citizens started Saturday afternoon and lasted until the early hours of Sunday. Police said unrest was reported in several places, including in the southern city of Bergen and the central city of Trondheim, while the situation was the worst in Oslo.

PHOENIX — Health officials in Arizona on Sunday reported 2,579 more COVID-19 cases and six additional deaths.

The latest numbers pushed the state’s totals to 1,804,369 cases and 19,812 known deaths since the pandemic began.

On Saturday, Arizona had reported 2,916 additional confirmed COVID-19 cases and 69 more deaths as the pace of virus deaths has nearly doubled over the past two weeks.

According to the Arizona Department of Health Services COVID-19 dashboard, there were 1,834 COVID-19 patients occupying inpatient hospital beds as of Friday — a level below the current surge’s peak of 2,103 on Sept. 12.

More than 4.1 million people (57.7% of the state’s population) have received at least one dose of vaccine and over 3.6 million residents are fully vaccinated (51.1% of the population).

NEW YORK -- New York City schools have been temporarily blocked from enforcing a vaccine mandate for its teachers and other workers by a federal appeals judge days before it was to take effect.

The mandate for the the nation’s largest school system was set to go into effect Monday.

But late Friday, a judge for the 2nd U.S. Circuit Court of Appeals granted a temporary injunction and referred the case to a three-judge panel an an expedited basis.

Department of Education spokesperson Danielle Filson said officials are seeking a speedy resolution by the circuit court next week.

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -2.80% 278.34 Delayed Quote.241.44%
PFIZER, INC. 0.70% 43.16 Delayed Quote.17.25%
All news about PFIZER, INC.
10/23PFIZER : United States Donates 1.4 Million More COVID-19 Pfizer Vaccines to Egypt Third Sh..
AQ
10/22Health Care Up On Defensive Bias -- Health Care Roundup
DJ
10/22PFIZER : says COVID-19 vaccine more than 90% effective in kids
AQ
10/22MODERNA : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines ma..
RE
10/22Walmart, Walgreens U.S. stores roll out Moderna, J&J COVID-19 booster shots
RE
10/22EXPLAINER : Is it time to get a COVID-19 booster? Which one?
AQ
10/22PFIZER : FDA Panel to Vote on Pfizer COVID-19 Shots for Kids; Data Shows Vaccine 90.7% Eff..
MT
10/22PFIZER : says studies show COVID-19 vaccine over 90% effective in kids 5-11
AQ
10/22PFIZER : Norway Stops Second Dose COVID-19 Vaccine Inoculations For Minors
MT
10/22PFIZER : BioNTech COVID-19 Vaccine Shows Nearly 91% Efficacy in Kids
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 557 M - -
Net income 2021 18 627 M - -
Net Debt 2021 29 307 M - -
P/E ratio 2021 12,7x
Yield 2021 3,66%
Capitalization 242 B 242 B -
EV / Sales 2021 3,33x
EV / Sales 2022 3,79x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 43,16 $
Average target price 45,72 $
Spread / Average Target 5,94%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.17.25%241 985
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
ELI LILLY AND COMPANY44.37%220 979
MERCK & CO., INC.-0.79%205 421